Are you an ovarian cancer survivor, patient, or caregiver? Don’t miss YOUR chance to learn what’s new in ovarian cancer treatments and research, and to meet others in the ovarian cancer community. Early Bird Registration is open! OCRA’s Ovarian Cancer National Conference® brings together people from across the country for a weekend of informative presentations, … Continued
(February 13, 2020) PARP inhibitors have shown to be a promising treatment option for a subset of ovarian cancer patients. As of February 2020, there are currently 3 FDA-approved PARP inhibitors for ovarian cancer: olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). In an interview with OncLive, Dr. Robert Coleman, a member of OCRA’s Scientific Advisory … Continued
OCRA is pleased to announce we have earned our tenth consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. We’re proud to again receive this rating, because it reflects our deep commitment to finding a cure for ovarian cancer, investing heavily in discovering new treatments, and hastening breakthroughs to fight this disease. A … Continued
(January 15, 2020) A new study in the Journal of the American Medical Association (JAMA) found no statistically significant association between self-reported use of powder in the genital area and subsequent risk of developing ovarian cancer. Published earlier this month, the study used a pooled analysis of 4 large US cohorts, including 252,745 women with … Continued
(January 13, 2020) Thanks to your support, 22 top scientists at 19 eminent medical centers across the world will delve into important topics across the ovarian cancer landscape. In 2020, along with our other ongoing grants and programs, OCRA is investing nearly $9 million in the fight against ovarian cancer. These grants, awarded internationally for … Continued
(January 6, 2020) For the past 14 years, OCRA has hosted Turn Up the Heat: Celebrating Female Superstars, a fabulous foodie fest packed full of tantalizing treats and eats from the most exciting female chefs, mixologists and restaurateurs, all for a good cause. And it is with profound gratitude for the opportunity to host this … Continued
(December 23, 2019) OCRA-funded scientist Dr. Sarah Gitto is making strides toward better harnessing the immune system to fight ovarian cancer. As reported recently in Gynecologic Oncology, Dr. Gitto and her colleagues at the University of Pennsylvania successfully created patient “avatars,” which mimic a patient’s biological profile based on a number of factors. Using these … Continued
WASHINGTON, D.C. – December 20, 2019 – Later today, President Trump is expected to sign into law a spending package that funds the government for the remainder of Fiscal Year (FY) 2020 and includes a significant increase in funding for the Ovarian Cancer Research Program (OCRP) at the Department of Defense (DoD). The legislation funds … Continued
(December 19, 2019) A cancer diagnosis can bring with it a bevy of complicated responses, including fear, anger, and even guilt. No one should have to navigate these tricky waters alone. Every day, OCRA’s Woman to Woman peer support programs across the country help hundreds of women diagnosed with gynecologic cancer receive the emotional support … Continued
OCRA-funded scientists have been hard at work this year, uncovering breakthroughs in ovarian cancer prevention, diagnostics, and treatment that can save women’s lives. Our grantees have made incredible progress toward better understanding and eradicating ovarian cancer. Their findings will have real-life impact for women and families battling this disease — and these stunning advancements would … Continued
It’s the season of giving, and all over the nation, OCRA Heroes are coming together to fundraise for ovarian cancer research. And they are extraordinary! I’m writing today to tell you about one of our most dedicated, vocal OCRA Heroes, Mai Linh Nguyen Achong. Mai Linh was diagnosed with ovarian cancer in 2008, when she … Continued
(December 3, 2019) The origins of high grade serous ovarian carcinoma (HGSOC) is a debated topic in the scientific community. Prior research has suggested the cancer arises from the fallopian tube epithelium, and other evidence supports the theory that ovarian surface epithelium cells are the site of origin. OCRA-funded research by Shuang Zhang, PhD, from … Continued
Get email updates about research news, action alerts, and ways to join the fight.
